Galera Therapeutics Inc. (OTC: GRTX)
$0.15
+0.0052 ( +3.71% ) 10.8M
Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. The Firm's lead product candidate, avasopasem manganese, is a highly selective small molecule dismutase mimetic for severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Firm's second product candidate, rucosopasem manganese, has been in development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).
Market Data
Open
$0.15
Previous close
$0.14
Volume
10.8M
Market cap
$6.52M
Day range
$0.10 - $0.25
52 week range
$0.07 - $3.09
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 13 | Mar 27, 2024 |
4 | Insider transactions | 1 | Feb 26, 2024 |
3 | Insider transactions | 1 | Jan 16, 2024 |
8-k | 8K-related | 14 | Nov 14, 2023 |
10-q | Quarterly Reports | 69 | Nov 14, 2023 |
3 | Insider transactions | 1 | Nov 13, 2023 |
8-k | 8K-related | 14 | Oct 31, 2023 |
8-k | 8K-related | 12 | Sep 26, 2023 |
8-k | 8K-related | 12 | Sep 22, 2023 |
8-k | 8K-related | 14 | Aug 14, 2023 |